Skip to main content

Dako, Pfizer Reach Companion Dx Deal

NEW YORK (GenomeWeb News) – Agilent Technologies company Dako today announced a companion diagnostic agreement with Pfizer.

The deal establishes a legal framework for the two firms to carry out R&D and commercialization work as well as advisory services, Dako said.

"This partnership with Dako will support Pfizer's companion diagnostics efforts, an important component of our growing precision medicine capabilities," John Hubbard, senior vice president of Development Operations at Pfizer, said in a statement. "Precision medicine R&D is designed to advance more targeted therapies for patients, improve efficacy, safety and success rates, and expedite development."

Financial and other terms of the alliance were not disclosed. Dako also did not provide specifics about drugs and disease areas of interest.

The deal is the second one covering the development of companion diagnostics forged by Dako since the start of the year, following a similar agreement with Eli Lilly announced last month. Agilent acquired Dako in June for $2.2 billion in a transaction that expands Agilent's footprint in the diagnostics space.

In addition to Pfizer and Eli Lilly, Dako has arrangements to develop companion diagnostics for Roche's Genentech and for Amgen.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.